Literature DB >> 1330796

Hepatitis type C virus infection in patients with type B chronic liver disease.

T Doi1, G Yamada, H Endo, H Nishimoto, M Takahashi, R Miyamoto, S Fujiki, H Shimomura, M Mizuno, T Tsuji.   

Abstract

Anti-c100-3 (Ortho) was determined in the sera of 152 patients with HBs antigen-positive chronic liver diseases to assess coinfection of hepatitis B virus (HBV) and hepatitis C virus (HCV). Eleven patients (7.2%) were positive for anti-c100-3. Anti-CP-9 (Okamoto) and HCV-RNA (RT-PCR) were also examined in these 11 patients. Anti-CP-9 was detected in 7 patients and HCV-RNA was detected in all 11 patients. Four of the 11 anti-c100-3-positive patients were positive for HBe antigen (HBeAg) and others were negative. In 8 of the 11 patients, HCV was suspected to be superinfected by blood transfusion. In HBeAg-positive patients, serum glutamic pyruvic transaminase (SGPT) was elevated in relation to active replication of HBV shown by DNA-polymerase activity. The histological findings showed chronic active hepatitis, with or without cirrhosis. On the other hand, in HBeAg-negative patients, SGPT fluctuated without evidence of active replication of HBV. Active inflammation in the liver was observed in 3 of 5 HBeAg-negative patients by liver biopsy. These findings suggest that HBV might play an important role in chronic active inflammation in HBeAg-positive patients coinfected with HCV, and that HCV might be responsible for continuous inflammation in HBeAg-negative patients coinfected with HCV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330796     DOI: 10.1007/bf02774976

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  28 in total

1.  The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

Authors:  T L Fong; A M Di Bisceglie; J G Waggoner; S M Banks; J H Hoofnagle
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

2.  Differentiation between specific and non-specific hepatitis C antibodies in chronic liver disease.

Authors:  J J Gray; T G Wreghitt; P J Friend; D G Wight; V Sundaresan; R Y Calne
Journal:  Lancet       Date:  1990-03-10       Impact factor: 79.321

3.  Liver disease in anti-HBe positive chronic HBsAg carriers and hepatitis C virus.

Authors:  G Fattovich; A Tagger; L Brollo; P Pontisso; G Realdi; P Perroni; A Alberti
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

4.  Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.

Authors:  J Bruix; J M Barrera; X Calvet; G Ercilla; J Costa; J M Sanchez-Tapias; M Ventura; M Vall; M Bruguera; C Bru
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

5.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV.

Authors:  J Tor; J M Llibre; M Carbonell; R Muga; A Ribera; V Soriano; B Clotet; M Sabriá; M Foz
Journal:  BMJ       Date:  1990-11-17

7.  Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience.

Authors:  D S Chen; G C Kuo; J L Sung; M Y Lai; J C Sheu; P J Chen; P M Yang; H M Hsu; M H Chang; C J Chen
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

8.  Permanent HBsAg clearance in chronic hepatitis B viral infection following acute delta superinfection.

Authors:  K P Chin; S Govindarajan; A G Redeker
Journal:  Dig Dis Sci       Date:  1988-07       Impact factor: 3.199

9.  Influence of hepatitis delta virus superinfection on the clearance of hepatitis B virus (HBV) markers in HBV carriers in Japan.

Authors:  H Ichimura; I Tamura; T Tsubakio; O Kurimura; T Kurimura
Journal:  J Med Virol       Date:  1988-09       Impact factor: 2.327

10.  Enzyme-linked immunosorbent assay for antibodies against the capsid protein of hepatitis C virus with a synthetic oligopeptide.

Authors:  H Okamoto; E Munekata; F Tsuda; K Takahashi; S Yotsumoto; T Tanaka; K Tachibana; Y Akahane; Y Sugai; Y Miyakawa
Journal:  Jpn J Exp Med       Date:  1990-08
View more
  1 in total

Review 1.  Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection.

Authors:  Seth D Crockett; Emmet B Keeffe
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-09-13       Impact factor: 3.944

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.